Sign in
Taking people in United StatesPhase 2

Tests reduced chemotherapy with an antibody treatment for children with neuroblastoma

Tests whether reduced chemotherapy plus an antibody is safe in children with high-risk neuroblastoma.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
New York, United StatesSee the site
Trial code
Registry title
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Status
Recruiting
Phase
Phase 2
People taking part
45 people, planned
Started
22 Jul 2024
Expected to end
22 Jul 2029
Type of study
Interventional
Treatments tested
  • DANYELZA
  • Sargramostim
  • Cytoxan
  • Topotecan
  • Vincristine
  • Doxorubicin
  • Ifosfamide
  • Etoposide
  • Carboplatin
  • Irinotecan
  • Temozolomide
  • Radiation Therapy
Record updated
28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with high-risk neuroblastoma who have had little or no chemotherapy so far.

Age
From 18 Months to 19 Years. The inclusion list says under 19 years.
Sex
All sexes can join.
Disease stage
High-risk neuroblastoma: MYCN-amplified stage L2/M/MS at any age, or stage M in children older than 18 months. Neuroblastoma must be confirmed by tissue exam, bone marrow spread plus high urine catecholamine levels, or a positive MIBG scan.
Earlier treatment
No more than one earlier cycle of high-risk neuroblastoma chemotherapy.
Biomarker or test result
MYCN amplification is required for stage L2/M/MS. It is not required for stage M in children older than 18 months.

Main reasons for not taking part

  • Severe problems with major organs (kidney, heart, liver, nerves, lungs, blood, gut), grade 3 or worse
  • Organ problems caused directly by the tumour or its spread do not count as a reason to exclude
  • Cannot follow the trial requirements
  • Pregnancy

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan
  • HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients >18 months old
  • No more than one prior cycle of HR-NB chemotherapy
  • Age <19 years
  • Signed informed consent indicating awareness of the investigational nature of this treatment

Who cannot take part

  • Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >/= to grade 3; °Organ dysfunction due to direct effects of primary tumor or metastatic disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., steroid- induced hyperglycemia or hypertension) will also not be considered in exclusion criteria
  • Inability to comply with protocol requirements
  • Pregnancy

Where in United States

  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Brian Kushner, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

The group in the trial

  • Participants with NeuroblastomaTreatment being tested

    Participants will receive 4 cycles of induction chemotherapy followed by a response-based intervention.

    Treatment: DANYELZA, Sargramostim, Cytoxan, Topotecan, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Carboplatin, Irinotecan, Temozolomide, and Radiation Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
N10: Reduced Therapy for High-Risk Neuroblastoma
Plain-language title
Tests reduced chemotherapy with an antibody treatment for children with neuroblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 August 2026